AzTrials
AzTrials

Research institution

City of Hope Medical Center Clinical Trials

Studies where City of Hope Medical Center is the lead sponsor: what is enrolling now, by phase, condition and country.

674 registered studies

In numbers

Open to volunteers
178
Active
327
With results posted
120
All registered
674

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 178

Completed, with results posted

All –
  • Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

    IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

    • Completed
    • Age: 18 years and older
    • Phase 1/2
    • Injection or infusion
    • Results posted

    This phase Ib/II trial studies the side effects of IRX-2, cyclophosphamide, and pembrolizumab work in treating participants with gastric or gastroesophageal junction cancer that has come back or that has spread to other places in…

    Conditions
    Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
    Trial name
    NCT03918499
    Testing
    Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab
    Where
    3 sites in United States
    Volunteers
    9 people
    Sponsor
    City of Hope Medical Center
    Can I take part? NCT03918499
  • Fallopian Tube Cancer, Peritoneal Cavity Cancer

    Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

    • Completed
    • Age: 18 years and older
    • Phase 2
    • Pill or oral medicine
    • Results posted

    RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

    Conditions
    Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
    Trial name
    NCT00538031
    Testing
    cyclophosphamide, celecoxib
    Where
    2 sites in United States
    Volunteers
    52 people
    Sponsor
    City of Hope Medical Center
    Can I take part? NCT00538031
  • Adenocarcinoma of the Prostate, Bone Metastases

    Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

    • Completed
    • Age: 18 years and older
    • Phase 2
    • Injection or infusion
    • Surgery or procedure
    • Results posted

    This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer.

    Conditions
    Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
    Trial name
    NCT01807065
    Testing
    sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
    Where
    3 sites in United States
    Volunteers
    51 people
    Sponsor
    City of Hope Medical Center
    Can I take part? NCT01807065
  • Advanced Lung Carcinoma, Malignant Female Reproductive System Neoplasm

    Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer

    • Completed
    • Age: All ages
    • Lifestyle or therapy programme
    • Results posted

    This trial will pilot a psychosocial intervention called Conquer Fear Support (CFS) in patients with stage III-IV lung or gynecologic cancer who are experiencing fear of cancer progression.

    Conditions
    Advanced Lung Carcinoma, Malignant Female Reproductive System Neoplasm, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
    Trial name
    NCT03776253
    Testing
    Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components), Questionnaire Administration
    Where
    United States
    Volunteers
    39 people
    Sponsor
    City of Hope Medical Center
  • HER2-positive Breast Cancer, Recurrent Breast Cancer

    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

    • Completed
    • Age: 19 years and older
    • Phase 2
    • Injection or infusion
    • Results posted

    This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast…

    Conditions
    HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
    Trial name
    NCT01730833
    Testing
    pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation
    Where
    3 sites in United States
    Volunteers
    63 people
    Sponsor
    City of Hope Medical Center
    Can I take part? NCT01730833

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in